Compare Crispr Therapeutics AG (CRSP) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Crispr Therapeutics AG trades at $53.94 (market cap $4.88B), while iShares 20 Plus Year Treasury Bond ETF trades at $77.9 (market cap $47.61B). The key difference: iShares 20 Plus Year Treasury Bond ETF is far larger — about 9.8× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| CRSP | TLT | |
|---|---|---|
Market Cap | $4.88B | $47.61B |
Volume | 2,861,747 | 49,263,490 |
Sector | Health | Fixed Income |
52-Week High | $74.92 | $92.06 |
52-Week Low | $44.34 | $77.11 |
Typical Hold Time | 77 Days | 83 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.71 with a slight 0.73% daily gain amid a challenging bond market environment. The technical picture remains bearish with moving averages signaling continued pressure, while oscillators show neutral momentum. Recent news highlights Treasury yields reaching multi-decade highs, with the fund down 11% year-to-date and 46% over five years as investors face a new era of higher interest rates.
The outlook for TLT remains pressured by rising interest rates and inflation concerns, though current yields near 5.3% offer attractive income potential. Key risks include further Fed tightening and economic uncertainty, while potential catalysts could emerge from any moderation in inflation or economic slowdown that might prompt rate cuts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
